WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

NCT04644289 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: olaparib
DRUG: durvalumab

Sponsor

AGO Research GmbH